News

February 6, 2018February 6, 2018

Cellectar Enrolls First DLBCL Patient in Phase 2 Trial Testing CLR 131 in Refractory B-cell Cancers

News

Cellectar Biosciences has recruited the first patient with diffuse large B-cell lymphoma (DLBCL) into its Phase 2 clinical trial testing the company’s lead investigational phospholipid-drug conjugate, CLR 131. The trial includes ... Read more

February 5, 2018February 5, 2018

Affimed’s AFM13 Shows High Response Rates in 2 Lymphoma Subtypes

News

AFM13, a bispecific antibody that recruits natural killer (NK) cells to the vicinity of a tumor, has shown promise in clinical trials of both Hodgkin’s lymphoma and in CD30-positive cutaneous ... Read more

February 2, 2018February 2, 2018

Aggressive Treatment Seen to Help Advanced Follicular Lymphoma Patients in Phase 2 Trial

News

Sequential chemoimmunotherapy, radioimmunotherapy, and maintenance treatment with Rituxan (rituximab) improves progression-free survival and delays disease progression in patients with untreated advanced follicular lymphoma, Phase 2 clinical trial data shows. The study reporting ... Read more

February 1, 2018February 1, 2018

Adcetris-Chemo Combo Delays Disease Progression in Newly-diagnosed Advanced Lymphoma, Trial Shows

News

Results from a Phase 3 clinical trial show that adding Adcetris (brentuximab vedotin) to a chemotherapy regimen reduces the risk of disease progression, death, or use of additional anticancer therapies for ... Read more

January 31, 2018January 31, 2018

New T-cell Therapy Shows Promise in Epstein-Barr Virus-positive Hodgkin’s Lymphoma

News

A new type of T-cell-based cancer immunotherapy may offer hope to people with Epstein-Barr virus-positive Hodgkin’s lymphoma, a small clinical trial showed. Importantly, the therapy was designed for use without ... Read more

January 30, 2018January 31, 2018

Gamida Recruiting Lymphoma Patients for Phase 1 Trial of Natural Killer Cell Therapy

News

Gamida Cell is enrolling participants in a Phase 1 clinical trial of its natural killer cell treatment for adults with relapsed or refractory non-Hodgkin’s lymphoma and multiple myeloma. The trial (NCT03019666) at ... Read more

January 29, 2018January 29, 2018

Pfizer’s Rituxan Biosimilar Equally Effective at Treating Follicular Lymphoma, Trial Shows

News

Pfizer‘s biosimilar therapy candidate PF-05280586 has shown equal effectiveness as Rituxan (rituximab) at treating indolent follicular lymphoma in a Phase 3 trial, the company announced. Indolent, or slow-growing, follicular lymphoma is ... Read more

January 26, 2018April 27, 2018

Phase 1 Trial of Curis and Aurigene’s Second Lymphoma Therapy is Underway

News

The first patient in a Phase 1 clinical trial of Curis and Aurigene’s oral lymphoma therapy has begun receiving it. CA-4948 is the second therapy from the partnership to reach clinical trials. It works by ... Read more

January 25, 2018

9 in 10 Mantle Cell Lymphoma Patients Benefit from Calquence, AstraZeneca Reports

News

Calquence (acalabrutinib) eliminated tumors in 40 percent of mantle cell lymphoma patients who took part in a Phase 2 clinical trial, AstraZeneca and Acerta Pharma reported. An additional 41 percent in the ACE-LY-004 trial ... Read more

January 24, 2018January 26, 2018

EU Approves Adcetris for Certain Types of Cutaneous T-cell Lymphoma

News

The European Commission has approved Adcetris (brentuximab vedotin) as a treatment for adults with cutaneous T-cell lymphoma (CTCL) whose cancer produces the CD30 molecule. It had previously given the therapy ... Read more